GLP-1–Based Therapy for Diabetes: What You Do Not Know Can Hurt You
Year: 2010
Type: article
Abstract: Proverbs, the oldest written version of the saying “What you don’t know can’t hurt you ” comes from Petit Palace, written in 1576 by G. Pettie: “So long as I know it not, it hurteth mee not.” In this issue of Diabetes Care, Drucker et al. (1) conclude that the safety profile of the newly available glucagon-like peptide 1 (GLP-1) class of drugs is favorable in comparison to their benefits as therapy, and the class of drugs might be considered as next in line after metformin for treatment for type 2 diabetes. The purpose of this counterpoint is to suggest such a conclusion is premature. History
Source: Diabetes Care
DOI: 10.2337/dc09-1902
Authors: Peter C. Butler, Sarah Dry, Robert Elashoff
Institution: University of California, Los Angeles
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W2140276611
